Hoechst (HOE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hoechst (HOE)

HMR 1.280

-1.5%

Nov 3 3:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Teddy who wrote (8)	5/7/1998 10:00:00 PM
From: Paul Senior	Read Replies (1) of 42

Teddy, thanks for posting this info. As I understand it, the operations that were sold were primarily manufacturers of generic pharmaceuticals. Per the information I have regarding HOE's life sciences businesses (p. 5 of invitation to annual general meeting) "HMR is concentrating its resources on discovering, developing and globally marketing innovative, patent-protected prescription drugs for important human indications... Generic drugs, over-the-counter drugs, and the production of standard active ingredients for third parties do not fit in with HMR's strategy and will be discontinued." So IMO, they are continuing to move forward here in implementing their strategy. Paul Senior

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next